To access this material please log in or register

Register Authorize

AII receptor blockers: modern possibilities of nephroprotection

Napalkov D. A.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: angiotensin receptor blockers, losartan, kidneys, proteinuria, diabetes mellitus

DOI: 10.18087/rhfj.2012.3.1695

ACEI and AII receptor blockers (ARB) are considered as agents not only providing adequate control of arterial pressure but having additional nephroprotective effects. Tolerance to ACEI is lower than that of ARB: such side effects as coughing and angioneurotic edema occur much less on sartan therapy than ACEI one. Randomized clinical studies on investigation of nephroprotective properties of ARB were conducted with Lozartan, Irbesartan, Valsartan and Telmisartan drugs predominantly in patients with Diabetes mellitus and chronic kidney disease of various degrees. The evidence basis on nephroprotective effect of this type of drugs is discussed in the literature review.
  1. Schmieder RE, Ruilope LM, Barnett AH. Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol. 2011;24 (5):569–580.
  2. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298 (17):2038–2047.
  3. Kramer H. Obesity and chronic kidney disease. Contrib Nephrol. 2006;151:1–18.
  4. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289 (1):76–79.
  5. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290 (2):199–206.
  6. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121 (4 Pt 1):1244–1263.
  7. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116 (4):263–272.
  8. Fliser D. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. J Nephrol. 2010;23 (4):369–376.
  9. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways media­ting physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20 (5):953–970.
  10. Hage FG, Venkataraman R, Zoghbi GJ et al. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol. 2009;53 (23):2129–2140.
  11. Yuyun MF, Adler AI, Wareham NJ. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? Curr Opin Nephrol Hypertens. 2005;14 (3):271–276.
  12. Mann JF, Yi QL, Gerstein HC. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl. 2004; (92):S59–62.
  13. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney Disease as a risk Factor for Development of Cardiovascular Disease. Circulation 2003;108 (17): 2154–2169.
  14. de Leeuw PW, Ruilope LM, Palmer CR et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med. 2004;164 (22):2459–2464.
  15. Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med. 2007;4 (9):e270.
  16. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36 (3):646–661.
  17. Lazarus JM, Bourgoigne JJ, Buckalew VM et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29 (2):641–650.
  18. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57 (5):1803–1817.
  19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329 (20):1456–1462.
  20. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118 (8):577–581.
  21. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334 (15):939–945.
  22. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349 (9069):1857–1863.
  23. Iino Y, Hayashi M, Kawamura T et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res. 2004;27 (1):21–30.
  24. Schmieder RE, Delles C, Mimran A et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30 (6):1351–1356.
  25. Parving HH, Lehnert H, Brochner-Martensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345 (12):870–878.
  26. Viberti G, Wheeldon NM. For the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106 (6):672–678.
  27. Zandbergen AA, Baggen MG, Lamberts SW et al. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med. 2003;139 (2):90–96.
  28. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351 (19):1952–1961
  29. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345 (12):861–869.
  30. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephro­pathy due to type 2 diabetes. N Engl J Med. 2001;345 (12):851–860.
Napalkov D. A. AII receptor blockers: modern possibilities of nephroprotection. Russian Heart Failure Journal. 2012;13(3):188-191

To access this material please log in or register

Register Authorize
Ru En